Oakley Capital Investments Limited has announced its investment in ProductLife Group, a European provider of outsourced regulatory and compliance services to the global life sciences industry. The indirect contribution via Fund V is anticipated to be approximately £41 million. ProductLife Group offers a range of services to the pharmaceutical industry and has experienced significant growth in recent years, with over 1,600 employees operating across 150+ countries globally. Oakley Capital plans to support the business' international expansion and invest in AI technology to enhance its services and operations. CEO Dr. Xavier Duburcq expressed excitement about the collaboration, citing the potential for organic and acquisition-driven expansion.